Leukocyte immunoglobulin-like receptor: Difference between revisions

Joel L. Sussman (talk | contribs)
No edit summary
Michal Harel (talk | contribs)
No edit summary
 
(8 intermediate revisions by 2 users not shown)
Line 1: Line 1:
<StructureSection load='' size='350' side='right' caption='Structure of human leukocyte immunoglobulin-like receptor ligand-binding domain (salmon) complex with class I MHC (aqua), β-2 microglobulin (green) and POL polyprotein peptide (pink) (PDB entry [[1p7q]])' scene='55/552188/Cv/3'>
<StructureSection load='' size='350' side='right' caption='Structure of human leukocyte immunoglobulin-like receptor ligand-binding domain (salmon) complex with class I MHC (aqua), β-2 microglobulin (green) and POL polyprotein peptide (pink) (PDB entry [[1p7q]])' scene='55/552188/Cv/3'>
    
    
'''Leukocyte immunoglobulin-like receptors''' (LIR) or '''CD85''' have extracellular immunoglobulin domains.  LIR modulates a variety of immune cells.  LIR interacts with class I MHC molecules<ref>PMID:19548123</ref>. <scene name='55/552188/Cv/4'>Leukocyte immunoglobulin-like receptor complex with class I MHC, β-2 microglobulin and POL polyprotein peptide</scene> (PDB entry [[1p7q]]). <scene name='55/552188/Cv/5'>Interactions between LIR and class I MHC, β-2 microglobulin</scene>.
'''Leukocyte immunoglobulin-like receptors''' (LIR) or '''CD85''' have extracellular immunoglobulin domains.  LIR modulates a variety of immune cells.  LIR interacts with class I MHC molecules<ref>PMID:19548123</ref>. <scene name='55/552188/Cv/6'>Leukocyte immunoglobulin-like receptor complex with class I MHC, β-2 microglobulin and POL polyprotein peptide</scene> (PDB entry [[1p7q]]). <scene name='55/552188/Cv/7'>Interactions between LIR and class I MHC, β-2 microglobulin</scene>.  
 
*'''LILRA2''' is an activating receptor that inhibits dendritic cell differentiation.
*'''LILRA5''' has a role in triggering innate immune responses.
*'''LILRB1''' interacts with classical and non-classical human leukocyte antigen (HLA) class I molecules<ref>PMID:37781391</ref>.
*'''LILRB3''' is a target for treatment against acute myeloid leukaemia<ref>PMID:38098451</ref>.
*'''LILRB4''' suppresses immunity in solid tumors<ref>PMID:33974041</ref>.
 
See also:
*[[Immune receptors]]
*[[Receptor]]
</StructureSection>
</StructureSection>


Line 9: Line 19:
{{#tree:id=OrganizedByTopic|openlevels=0|
{{#tree:id=OrganizedByTopic|openlevels=0|


*LIR-1
*LILR; ligand-binding domain D1D2 27-221; ligand-binding domain D3D4 222-417
 
*LILRA2 subfamily A member 2
 
**[[2otp]] – hLILRA2 ligand-binding domain D1D2 - human<br />
 
*LILRA3 subfamily A member 3
 
**[[3q2c]] – hLILRA3 N-terminal domain  <br />
 
*LILRA5 subfamily A member 5
 
**[[2d3v]] – hLILRA5 extracerllular domain  <br />
**[[1vdg]] – hLILRA5 ligand-binding domain D1D2 (mutant) <br />


**[[1g0x]], [[1ufu]] – hLIR-1 ligand-binding domain D1D2– human <br />
*LILRB1 subfamily B member 1
**[[1ugn]], [[1vdg]] – hLIR-1 ligand-binding domain D1D2 (mutant) <br />
**[[4ll9]] – hLIR-1 ligand-binding domain D3D4 <br />


*LIR-2
**[[1g0x]] – hLILRB1 ligand-binding domain D1D2<br />
**[[1ugn]] – hLILRB1 ligand-binding domain D1D2 (mutant) <br />
**[[4ll9]] – hLILRB1 ligand-binding domain D3D4 <br />
**[[7kfk]] – hLILRB1 ligand-binding domain D3D4 + Rifin<br />
**[[6zdx]] – hLILRB1 ectodomain + Rifin<br />
**[[1p7q]] – hLILRB1 ligand-binding domain D1D2 + class I MHC + β-2 microglobulin +  POL polyprotein peptide<br />
**[[4no0]], [[5knm]], [[6aee]], [[6ewa]], [[6ewc]], [[6ewo]], [[6k60]] – hLILRB1 ligand-binding domain D1D2 + class I MHC + β-2 microglobulin +  peptide<br />
**[[3d2u]] – hLILRB1 ligand-binding domain D1D2 + herpesvirus UL18 + β-2 microglobulin +  actin peptide<br />


**[[4lla]] – hLIR-2 ligand-binding domain D3D4 <br />
*LILRB2 subfamily B member 2
**[[2otp]] – hLIR-2 ligand-binding domain D1D2 <br />
**[[2dyp]] – hLIR-2 ligand-binding domain D1D2 + class I MHC + β-2 microglobulin +  H2A peptide<br />


*LIR-4
**[[4lla]] – hLILRB2 ligand-binding domain D3D4 <br />
**[[6aed]] – hLILRB2 ligand-binding domain D1D2D3D4 (mutant)<br />
**[[2gw5]] – hLILRB2 ligand-binding domain D1D2 <br />
**[[6bcs]] – hLILRB2 ligand-binding domain D1D2 + benzamidine<br />
**[[2dyp]] – hLILRB2 ligand-binding domain D1D2 + class I MHC + β-2 microglobulin +  H2A peptide<br />


**[[3q2c]] – hLIR-4 N-terminal domain  <br />
*LILRB3 subfamily B member 3


*LIR-5
**[[6grq]], [[6grs]], [[6grt]] – mLILRB3 extracellular domain 25-619 <br />


**[[3p2t]] – hLIR-5 ligand-binding domain D1D2 <br />
*LILRB4 subfamily B member 4


*LIR-1 complexes
**[[3p2t]] – hLILRB4 ligand-binding domain D1D2 <br />
**[[6k7o]] – hLILRB4 N-terminal domain + antibody <br />


**[[1p7q]] – hLIR-1 ligand-binding domain D1D2 + class I MHC + β-2 microglobulin +  POL polyprotein peptide<br />
**[[5knm]] – hLIR-1 ligand-binding domain D1D2 + class I MHC + β-2 microglobulin +  peptide<br />
**[[4no0]] – hLIR-1 ligand-binding domain D1D2 + class I MHC + β-2 microglobulin +  lymphocyte-specific protein peptide<br />
**[[3d2u]] – hLIR-1 ligand-binding domain D1D2 + herpesvirus UL18 + β-2 microglobulin +  actin peptide<br />
}}
}}
== References ==
== References ==
<references/>
<references/>
[[Category:Topic Page]]
[[Category:Topic Page]]

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Michal Harel, Alexander Berchansky, Joel L. Sussman